AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03657420
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
Trial: NCT03657420
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone is a steroid which is believed to kill cancer cells
Trial: NCT00249301
Drug: MLN8054
RxNorm normalized name: MLN8054
DrugBank: MLN8054 (DB13061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
Trial: NCT00863655
Drug: Everolimus Placebo
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Trial: NCT00869622
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mgs/week + calcium and vit d
Trial: NCT01894386
Drug: FF 400 mcg
RxNorm normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
Trial: NCT01894386
Drug: UMEC 500 mcg
RxNorm normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125 mcg powder for inhalation delivered by DPI
Trial: NCT01894386
Drug: UMEC 250 mcg
RxNorm normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 62.5 mcg powder for inhalation delivered by DPI
Trial: NCT01894386
Drug: VI 100 mcg
RxNorm normalized name: azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mcg powder for inhalation delivered by DPI
Trial: NCT00000122
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02770794
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discontinue infliximab; receive Infliximab when relapse
Trial: NCT01703572
Drug: OMP-52M51
RxNorm normalized name: OMP-52M51
DrugBank: Brontictuzumab (DB12737)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04735523
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran dispensing claim is used as the exposure group
Trial: NCT04735523
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin dispensing claim is used as the reference group
Trial: NCT03403140
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week
Trial: NCT01051791
Drug: Everolimus 10mg daily
RxNorm normalized name: everolimus 10 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
Trial: NCT00802230
Drug: Terbutaline Infusion
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03498430
Drug: Copanlisib (Aliqopa, BAY80-6946)
RxNorm normalized name: copanlisib Injection [Aliqopa]
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
Trial: NCT01107522
Drug: CTO
RxNorm normalized name: Actos
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
Trial: NCT03074825
Drug: Chiauranib
RxNorm normalized name: Chiauranib
DrugBank: Chiauranib (DB16124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 50mg orally once daily
Trial: NCT04494503
Drug: APG-2575
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-2575 orally once daily, every 28 days as a cycle.
Trial: NCT04494503
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
Trial: NCT04494503
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
Trial: NCT03825796
Drug: Enasidenib Mesylate
RxNorm normalized name: Enasidenib Mesylate
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03825796
Drug: Liposome-encapsulated Daunorubicin-Cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03809663
Drug: Tezepelumab
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT02183324
Drug: Medium dose of BI 1356 BS
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183324
Drug: High dose of BI 1356 BS
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01051596
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150mg/m2 Days 1-5 of each 28 day cycle
Trial: NCT01051596
Drug: ABT-888
RxNorm normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg orally BID Days 1-7 of each 28 day cycle
Trial: NCT00216580
Drug: Risperidone, long-acting injectable
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01285362
Drug: Fish Oil Supplementation
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
Trial: NCT01707394
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04633967
Drug: Alemtuzumab Injection
RxNorm normalized name: alemtuzumab Injection
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This observational study is collecting clinical data focusing on infusion associated reactions and changes in vital signs in MS patients Novel Infusion protocol: The protocol consisted of the following Pre-infusion Protocol~Premedication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days prior to the infusion.~Premedication with 50 mg of prednisone orally for 5 days before the infusion.~During Infusion Protocol During infusions methylprednisolone is administered in a dosage of 500 mg on every day of the infusion.~Post Infusion Medication~Post-medication with an H1 and H2 blockade (ranitidine or similar, loratadine or similar) for 7 days after the infusion.~Post-medication with 50 mg of prednisone orally for 5 days after the infusion.~Medications to be used PRN throughout the peri-infusion protocol Benadryl, acetaminophen or other analgesics were allowed
Trial: NCT00175123
Drug: Botulinum A toxin
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intravesical injection. 12 IE/kg b.w.
Trial: NCT04479436
Drug: Patritumab Deruxtecan
RxNorm normalized name: patritumab deruxtecan
DrugBank: Patritumab (DB12090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
Trial: NCT00751062
Drug: timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
Trial: NCT04570839
Drug: COM701 in combination with BMS-986207 and nivolumab.
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
Trial: NCT03004638
Drug: MEDI6012 40 mg
RxNorm normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
Trial: NCT03004638
Drug: MEDI6012 120 mg
RxNorm normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
Trial: NCT03004638
Drug: MEDI6012 300 mg
RxNorm normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
Trial: NCT03004638
Drug: MEDI6012 IV Push
RxNorm normalized name: MEDI6012
DrugBank: MEDI6012 (DB14833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
Trial: NCT01139775
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered intravenously as a continuous 10-minute infusion
Trial: NCT01139775
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a continuous 1-hour infusion
Trial: NCT03146806
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse.
Trial: NCT03238560
Drug: Montelukast Chewable Tablet
RxNorm normalized name: montelukast Chewable Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast treatment was used at a dosage of 5mg/day once daily
Trial: NCT00758290
Drug: Triclosan/Fluoride
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily for 3 weeks
Trial: NCT00758290
Drug: Fluoride/triclosan
RxNorm normalized name: Sodium Fluoride/Triclosan Topical application Paste
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush daily for 3 weeks
Trial: NCT04733066
Drug: Teduglutide
RxNorm normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intervention group consists of patients, who receive teduglutide within routine medical care
Trial: NCT01131169
Drug: busulfan, melphalan and fludarabine
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is \> 125% ideal body weight and should be calculated on adjusted ideal body weight.
Trial: NCT00014495
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02707484
Drug: Thalidomide (100mg)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
Trial: NCT02707484
Drug: Thalidomide (50mg)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
Trial: NCT01882985
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03894826
Drug: Vorinostat 100 MG
RxNorm normalized name: vorinostat 100 MG
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
Trial: NCT00984542
Drug: bendamustine hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
Trial: NCT02921685
Drug: Monalizumab
RxNorm normalized name: Monalizumab
DrugBank: Monalizumab (DB12824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four dose levels will be tested.
Trial: NCT02940756
Drug: artesunate-amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
Trial: NCT02940756
Drug: Dihydroartemisinine-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
Trial: NCT00608777
Drug: Calcipotriene/betamethasone
RxNorm normalized name: calcipotriene/betamethasone 0.005 %-0.064 % TOPICAL FOAM (GRAM)
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
Trial: NCT02734537
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03187730
Drug: Nicotine Replacement Therapy (NRT)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in both arms will be eligible to receive a free four-week supply of NRT.
Trial: NCT01231451
Drug: DMPA
RxNorm normalized name: DMPA
DrugBank: Zytron (DB11768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will take DMPA
Trial: NCT04084951
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: programmed cell death ligand 1 (PD-L1) blocking antibody
Trial: NCT04084951
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody
Trial: NCT04084951
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: programmed cell death 1 (PD-1) blocking antibody
Trial: NCT01760174
Drug: Ropivacaine bolus in transversus abdominis plane catheter
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours.
Trial: NCT02585947
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
Trial: NCT01061112
Drug: Tolbutamide Control - Tolbutamide Only
RxNorm normalized name: Tolbutamide
DrugBank: Tolbutamide (DB01124)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
Trial: NCT01061112
Drug: Tolbutamide Inhibition - Tolbutamide & Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Trial: NCT00020787
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
Trial: NCT00714857
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
Trial: NCT01827111
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
Trial: NCT01827111
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
Trial: NCT00486785
Drug: Alfuzosin
RxNorm normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10mg Once Daily for 24 weeks
Trial: NCT03920839
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCMGA00012 administered intravenously every 3 weeks.
Trial: NCT03920839
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
Trial: NCT03920839
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered intravenously on Day 1 of 21-day cycles.
Trial: NCT03920839
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed administered intravenously on Day 1 of 21-day cycles.
Trial: NCT03920839
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
Trial: NCT03920839
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered intravenously on Day 1 of 21-day cycles.
Trial: NCT02841839
Drug: Stannous Fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05867602
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous human albumin at a dose of (1g/kg), with a minimum dose of 50g and a maximum dose of 100g
Trial: NCT00723502
Drug: Finafloxacin + Amoxicillin
RxNorm normalized name: Finafloxacin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
Trial: NCT00723502
Drug: Finafloxacin + Esomeprazole
RxNorm normalized name: Finafloxacin
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
Trial: NCT02726009
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes